Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H19N3S.2ClH |
| Molecular Weight | 358.329 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CN(C)CCCN1C2=CC=CC=C2SC3=CC=CN=C13
InChI
InChIKey=NESOWNBCLCBENO-UHFFFAOYSA-N
InChI=1S/C16H19N3S.2ClH/c1-18(2)11-6-12-19-13-7-3-4-8-14(13)20-15-9-5-10-17-16(15)19;;/h3-5,7-10H,6,11-12H2,1-2H3;2*1H
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
18 ng/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROTHIPENDYL serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
42.6 ng/mL |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROTHIPENDYL serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.5 h |
unknown, oral |
PROTHIPENDYL unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1280 mg 1 times / day multiple, oral Studied dose Dose: 1280 mg, 1 times / day Route: oral Route: multiple Dose: 1280 mg, 1 times / day Sources: |
unhealthy, 20 years (range: 16-31 years) Health Status: unhealthy Age Group: 20 years (range: 16-31 years) Sex: M Sources: |
|
960 mg 1 times / day multiple, oral Studied dose Dose: 960 mg, 1 times / day Route: oral Route: multiple Dose: 960 mg, 1 times / day Sources: |
unhealthy, 26 years (range: 14-42 years) Health Status: unhealthy Age Group: 26 years (range: 14-42 years) Sex: F Sources: |
|
4 g single, oral Overdose |
unknown |
Other AEs: Adverse event... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Adverse event | grade 5 | 4 g single, oral Overdose |
unknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The impact of perfectionism and anxiety traits on action monitoring in major depressive disorder. | 2010-07 |
|
| Research on antipsychotics in India. | 2010-01 |
|
| Increased D-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. | 2009-12 |
|
| A double-blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow-release oral morphine versus methadone in opioid-dependent in-patients willing to undergo detoxification. | 2009-09 |
|
| Psychotropic medication use among nursing home residents in Austria: a cross-sectional study. | 2009-05-21 |
|
| Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. | 2007-06 |
|
| Fatal accident caused by isoflurane abuse. | 2002-12 |
|
| Application of ammonium peroxidisulfate and metavanadate for spectrophotometric determination of prothipendyl hydrochloride. | 2001-08-15 |
|
| Different fatal toxicity of neuroleptics identified by autopsy. | 2001-04 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m9268
Created by
admin on Mon Mar 31 21:33:02 GMT 2025 , Edited by admin on Mon Mar 31 21:33:02 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID00148471
Created by
admin on Mon Mar 31 21:33:02 GMT 2025 , Edited by admin on Mon Mar 31 21:33:02 GMT 2025
|
PRIMARY | |||
|
1082713-52-7
Created by
admin on Mon Mar 31 21:33:02 GMT 2025 , Edited by admin on Mon Mar 31 21:33:02 GMT 2025
|
PRIMARY | |||
|
6Y73598336
Created by
admin on Mon Mar 31 21:33:02 GMT 2025 , Edited by admin on Mon Mar 31 21:33:02 GMT 2025
|
PRIMARY | |||
|
71587927
Created by
admin on Mon Mar 31 21:33:02 GMT 2025 , Edited by admin on Mon Mar 31 21:33:02 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
